Just three years ago, DNA testing company 23andMe was the golden child of Wall Street and Silicon Valley. Today, the firm is at risk of being delisted from the Nasdaq.
But 23andMe’s CEO, Anne Wojcicki, tells CNN that Wall Street shouldn’t count her out yet.
Despite the firm’s initial popularity, the former tech unicorn’s funds have dried up and its value has dropped a stunning 96% since its peak share price of $17.65 in February 2021.
Shares of 23andMe are now priced at about $0.70, and in November the company
→ Continue reading at CNN - Business News